可吸收缝线与不可吸收缝线在瘢痕疙瘩及增生性瘢痕切除缝合中对术后复发率的影响比较

注册号:

Registration number:

ChiCTR2000037712 

最近更新日期:

Date of Last Refreshed on:

2021-06-28 22:54:01 

注册时间:

Date of Registration:

2020-08-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

可吸收缝线与不可吸收缝线在瘢痕疙瘩及增生性瘢痕切除缝合中对术后复发率的影响比较

Public title:

Comparison of the effect of absorbable suture and non-absorbable suture on postoperative recurrence rate in the excision of keloid and hypertrophic scar

注册题目简写:

English Acronym:

研究课题的正式科学名称:

可吸收缝线与不可吸收缝线在瘢痕疙瘩及增生性瘢痕切除缝合中对术后复发率的影响比较

Scientific title:

Comparison of the effect of absorbable suture and non-absorbable suture on postoperative recurrence rate in the excision of keloid and hypertrophic scar

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

卢孔烨 

研究负责人:

李平松 

Applicant:

Kongye Lu 

Study leader:

Pingsong Li 

申请注册联系人电话:

Applicant telephone:

+86 19962593396

研究负责人电话:

Study leader's
telephone:

+86 13338846588

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lukongye@icloud.com

研究负责人电子邮件:

Study leader's E-mail:

840734786@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

南通西路98号

研究负责人通讯地址:

南通西路98号

Applicant address:

98 Nantong Road West, Guangling District, Nantong, Jiangsu, China

Study leader's address:

98 Nantong Road West, Guangling District, Nantong, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

苏北人民医院

Applicant's institution:

North Jiangsu People's Hospital

研究负责人所在单位:

苏北人民医院

Affiliation of the Leader:

North Jiangsu People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020ky-050

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

苏北人民医院伦理委员会

Name of the ethic committee:

North Jiangsu People's Hospital Ethic Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2020-08-17 00:00:00

伦理委员会联系人:

曹文学

Contact Name of the ethic committee:

Wenxue Cao

伦理委员会联系地址:

南通西路98号

Contact Address of the ethic committee:

98 Nantong Road West, Guangling District, Nantong, Jiangsu, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

苏北人民医院烧伤整形科

Primary sponsor:

Department of Plastic Surgery and Burns, North Jiangsu People's Hospital

研究实施负责(组长)单位地址:

南通西路98号

Primary sponsor's address:

98 Nantong Road West, Guangling District, Nantong, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

扬州

Country:

China

Province:

Jiangsu

City:

Yangzhou

单位(医院):

苏北人民医院烧伤整形科

具体地址:

南通西路98号

Institution
hospital:

Department of Plastic Surgery and Burns, North Jiangsu People's Hospital

Address:

98 Nantong Road West

经费或物资来源:

自筹

Source(s) of funding:

Self-collected funds

研究疾病:

瘢痕疙瘩和增生性瘢痕  

Target disease:

Keloid and hypertrophic scar

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较可吸收缝线与不可吸收缝线在瘢痕疙瘩及增生性瘢痕切除缝合中对术后瘢痕疙瘩复发率及术后瘢痕形成及美观程度的影响。  

Objectives of Study:

To compare the effect of absorbable sutures and non-absorbable sutures on postoperative keloid recurrence rate, postoperative scar formation and aesthetic degree in the excision and suturing of hypertrophic keloid, in order to guide clinical practice, provide evidence basis for clinical practice, and improve the therapeutic effect of keloid

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.有长期户外工作的需要;
2.患有影响切口愈合的疾病;如坏血症、成骨不全症、Ehlers-Danlos综合征等;
3.患有严重心、肝、肾功能不全,糖尿病等其他疾病者;
4.患有精神疾病,包括严重的癔症,不具备自主能力者;
5.对所用缝线及药物过敏或不耐受者;
6.最近3个月参加过其他临床试验;
7.任何病史,据研究者判断可能干扰实验结果或增加患者风险;
8.研究者判断依从性不好,不能严格执行方案。

Exclusion criteria:

1. Patients who need long-term outdoor work;
2. Patients with diseases affecting wound healing, such as pernicious disease, osteogenesis imperfecta, Ehlers Danlos syndrome, etc;
3. Patients with severe heart, liver and kidney dysfunction, diabetes and other diseases;
4. Patients with mental illness, including severe hysteria, do not have autonomy;
5. Patients who are allergic or intolerant to the sutures and drugs used;
6. Patients who have participated in other clinical trials in the last three months;
7. Patients with any medical history may interfere with the experimental results or increase the risk of patients according to the judgment of the researchers;
8. The researcher judged the patients who had poor compliance and could not strictly implement the protocol.

研究实施时间:

Study execute time:

From 2020-09-30 00:00:00 To 2022-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-09-30 00:00:00 To 2021-09-30 00:00:00

干预措施:

Interventions:

组别:

A

样本量:

35

Group:

A

Sample size:

干预措施:

使用慢微乔缝线

干预措施代码:

Intervention:

using vircyl suture material

Intervention code:

组别:

B

样本量:

35

Group:

B

Sample size:

干预措施:

使用prolene缝线

干预措施代码:

Intervention:

using prolene suture material

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

扬州 

Country:

China

Province:

Jiangsu

City:

Yangzhou

单位(医院):

苏北人民医院 

单位级别:

三级甲等 

Institution
hospital:

North Jiangsu People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

瘢痕疙瘩复发率

指标类型:

主要指标

Outcome:

recurrence rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 50 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究者李平松使用随机数表法产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Pingsong Li, a researcher, uses the random number table method to generate random sequences

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022年九月通过ResMan临床试验公共管理平台公开, http://www.medresman.org.cn。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan Clinical Trial Management Public Platform by Sep. 2020, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用ResMan平台

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan Clinical Trial Management Public Platform

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-08-30 22:50:32